Abstract
Multiple myeloma (MM) is due to the proliferation in the bone marrow of malignant plasmacells and accounts for about 10% of all hematological tumors. MM is the natural evolution of a monoclonal gammopathy of uncertain significance. Although the introduction of novel biological agents in the clinical practice has changed the natural history of the disease, MM remains incurable. MicroRNAs (miRNAs) are short non-coding RNAs that control cell functions through mRNA targeting. In the cancer setting, miRNAs have shown prognostic and predictive potentials. Several preclinical findings demonstrate their broad anticancer activities in various types of cancer, including MM. In this article, we provide an overview of the biology of miRNAs focusing on the role of miRNA deregulation in MM pathogenesis. These findings represent the basis to discuss the potential role of miRNAs as therapeutic agents against MM.
Keywords: Bone disease, microRNA, multiple myeloma, non-coding RNA, target therapy.
Current Pharmaceutical Biotechnology
Title:MicroRNA and Multiple Myeloma: from Laboratory Findings to Translational Therapeutic Approaches
Volume: 15 Issue: 5
Author(s): Marco Rossi, Nicola Amodio, Maria Teresa Di Martino, Pierosandro Tagliaferri, Pierfrancesco Tassone and William C. Cho
Affiliation:
Keywords: Bone disease, microRNA, multiple myeloma, non-coding RNA, target therapy.
Abstract: Multiple myeloma (MM) is due to the proliferation in the bone marrow of malignant plasmacells and accounts for about 10% of all hematological tumors. MM is the natural evolution of a monoclonal gammopathy of uncertain significance. Although the introduction of novel biological agents in the clinical practice has changed the natural history of the disease, MM remains incurable. MicroRNAs (miRNAs) are short non-coding RNAs that control cell functions through mRNA targeting. In the cancer setting, miRNAs have shown prognostic and predictive potentials. Several preclinical findings demonstrate their broad anticancer activities in various types of cancer, including MM. In this article, we provide an overview of the biology of miRNAs focusing on the role of miRNA deregulation in MM pathogenesis. These findings represent the basis to discuss the potential role of miRNAs as therapeutic agents against MM.
Export Options
About this article
Cite this article as:
Rossi Marco, Amodio Nicola, Martino Teresa Di Maria, Tagliaferri Pierosandro, Tassone Pierfrancesco and Cho C. William, MicroRNA and Multiple Myeloma: from Laboratory Findings to Translational Therapeutic Approaches, Current Pharmaceutical Biotechnology 2014; 15 (5) . https://dx.doi.org/10.2174/1389201015666140519104743
DOI https://dx.doi.org/10.2174/1389201015666140519104743 |
Print ISSN 1389-2010 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4316 |
Call for Papers in Thematic Issues
Artificial Intelligence in Bioinformatics
Bioinformatics is an interdisciplinary field that analyzes and explores biological data. This field combines biology and information system. Artificial Intelligence (AI) has attracted great attention as it tries to replicate human intelligence. It has become common technology for analyzing and solving complex data and problems and encompasses sub-fields of machine ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Antidepressant Desipramine Leads to C6 Glioma Cell Autophagy: Implication for the Adjuvant Therapy of Cancer
Anti-Cancer Agents in Medicinal Chemistry Patents on Immunotoxins and Chimeric Toxins for the Treatment of Cancer
Recent Patents on Drug Delivery & Formulation Neurotrophic Factor Treatment After Spinal Root Avulsion Injury
Central Nervous System Agents in Medicinal Chemistry Multidrug Resistance: Retrospect and Prospects in Anti-Cancer Drug Treatment
Current Medicinal Chemistry Role of Ascorbic Acid in Cardiovascular Performance During Acute Hemorrhage
Vascular Disease Prevention (Discontinued) Apoptosis: A Key in Neurodegenerative Disorders
Current Neurovascular Research Targeting Parkinson’s - Tyrosine Hydroxylase and Oxidative Stress as Points of Interventions
CNS & Neurological Disorders - Drug Targets Current Concepts and Future Directions in Radioimmunotherapy
Current Drug Discovery Technologies Use of Peripheral Blood Stem Cells in Tissue Engineering
Current Tissue Engineering (Discontinued) Alzheimer´s Disease and Oxidative Stress: A Review
Current Medicinal Chemistry Potential Role of Natural Compounds as Anti-Angiogenic Agents in Cancer
Current Vascular Pharmacology Neurotoxicity Induced by Mephedrone: An up-to-date Review
Current Neuropharmacology Neuroprotective Role of Nanoparticles Against Alzheimer's Disease
Current Drug Metabolism Recent Development of Peptide Drugs and Advance on Theory and Methodology of Peptide Inhibitor Design
Medicinal Chemistry CD95 Signaling in Cancer Treatment
Current Pharmaceutical Design Prolyl Oligopeptidase, Inositol Phosphate Signalling and Lithium Sensitivity
CNS & Neurological Disorders - Drug Targets The Caveolin-1 Connection to Cell Death and Survival
Current Molecular Medicine CD248: Reviewing its Role in Health and Disease
Current Drug Targets Mechanisms of Tumor Cell Necrosis
Current Pharmaceutical Design Dual Targeting of Glioma U251 Cells with Nanoparticles Prevents Tumor Angiogenesis and Inhibits Tumor Growth
Current Neurovascular Research